Results 111 to 120 of about 21,457 (213)

Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

Pediatric Rheumatology Online Journal
Background In 2018, intravenous abatacept was approved for the treatment of refractory polyarticular-course juvenile idiopathic arthritis (JIA) in Japan.
Tomo Nozawa, Naomi Iwata, Toru Igarashi, Ichiro Kobayashi, Shoji Ota, Takako Yamada, Etsuya Bando, Katsuyoshi Habiro, Syuji Takei   +8 more
doaj   +1 more source

Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey

Rheumatology &Autoimmunity, EarlyView.
Haojie Xu, Liyun Zhang, Yuehong Huo, Rui Wu, Lijun Wu, Ling Lei, Linyu Geng, Chunyu Tan, Xiaomei Li, Ru Li, Yin Su, the Women's Rheumatoid Arthritis Research Collaborative Group   +11 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis

Journal of Internal Medicine, Volume 299, Issue 6, Page 741-753, June 2026.
Abstract Objectives To investigate, in early rheumatoid arthritis, whether bridging with glucocorticoids (GCs) is associated with an increased risk of flare following GC tapering and withdrawal. Methods A total of 810 NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD‐STAR) patients were included in this post hoc analysis: all received ...
Kristina Lend, Jos W. R. Twisk, Frieda A. Koopman, Anna Rudin, Merete Lund Hetland, Till Uhlig, Dan C. Nordström, Michael T. Nurmohamed, Bjorn Gudbjornsson, Kim Hørslev‐Petersen, Marte Schrumpf Heiberg, Tuulikki Sokka‐Isler, Gerdur Grondal, Espen A. Haavardsholm, Mikkel Østergaard, Jon Lampa, Ronald van Vollenhoven   +16 more
wiley   +1 more source

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Clinical and Developmental Immunology, 2013
Introduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/
Kei Ikeda, Yoshie Sanayama, Sohei Makita, Junichi Hosokawa, Mieko Yamagata, Daiki Nakagomi, Katsuhiko Takabayashi, Hiroshi Nakajima   +7 more
doaj   +1 more source

Adherence in Rheumatoid Arthritis patients assessed with a validated Italian version of the 5-item compliance questionnaire for rheumatology [PDF]

, 2019
OBJECTIVES: The 5-item Compliance Questionnaire for Rheumatology (CQR5) proved reliability and validity in respect of identification of patients likely to be high adherers (HAs) to anti-rheumatic treatment, or low adherers (LAs), i.e ...
Astorri, D., Azzolina , D., Botsios, C., Done, John, Doria, A, Favero, M, Friso, L, Gregori, D, Ometto, Francesca, Raffeiner, B.   +9 more
core  

Immunosuppressive Medications and Nonserious Infections in People With Rheumatoid Arthritis: A Prospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective People with rheumatoid arthritis (RA) are at increased risk of serious infection, but less is known about nonserious infections. Our prospective cohort study evaluated associations between medications for RA and the risk of nonserious infections.
Michael D. George, Kelly Gavigan, Shilpa Venkatachalam, David Curtis, Laura Stradford, W. Benjamin Nowell, Joshua F. Baker, Fenglong Xie, Jeffrey R. Curtis   +8 more
wiley   +1 more source

Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective Immunocompromised individuals with rheumatic conditions have heightened risk of tuberculosis (TB) infection, reactivation, and severe disease. Patients with social risks are especially vulnerable. After an alert of increased TB rates among individuals experiencing homelessness in Massachusetts, we leveraged the existing social risk screening ...
Rebecca Summit, Dylan B. Tierney, Taussia Boadi, Tyler Green, Karli Retzel, Virginia Bills, Nancy A. Shadick, Leah Santacroce, Sara R. Schoenfeld, Candace H. Feldman   +9 more
wiley   +1 more source

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations

Biologics: Targets & Therapy, 2014
Alvin F Wells,1,2 Nicole Jodat,1 Michael Schiff3 1Rheumatology and Immunotherapy Center, Franklin, WI, USA; 2Duke University Medical Center, Durham, NC, USA; 3University of Colorado, School of Medicine, Denver, CO, USA Abstract: There are now more ...
Wells AF, Jodat N, Schiff M
doaj  

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitor (ICI) therapies are known to cause immune‐related adverse events (irAEs), including life‐threatening myocarditis, myositis, and myasthenia (MMM) overlap syndrome. Current literature lacks established therapeutic guidelines for effective management with steroid‐sparing agents.
Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury, Ernest Algabre   +3 more
wiley   +1 more source